Strategic Expansion ZeptoMetrix is actively expanding its infectious disease diagnostics portfolio with new controls and quantitative standards (for influenza A H5N1) and phage-like particle technology, signaling opportunities to cross-sell enhanced QA products, custom controls, and integrated diagnostic panels to research labs and contract developers.

Quality & Compliance The company has obtained IVDR Quality Management System certification from BSI, underscoring a strong compliance foundation that can be leveraged to pursue higher-value regulated markets, government and hospital procurement, and longer-term service contracts.

Strategic Partnerships Recent collaborations with LEX Diagnostics and ongoing custom control development indicate a receptive path for expanding co-developed controls, system-integrated solutions, and tailored QA workflows for platform users, opening doors for multi-year licensing and support agreements.

Diversified Risk A broad product line in NATtrol molecular controls, respiratory and coronavirus panels, and PLP-based technologies suggests opportunities to upsell bundled kits, training, and validation services to labs seeking turnkey quality assurance and performance verification across assays.

Market Readiness With a revenue range of 50 to 100 million and a mid-sized team, ZeptoMetrix presents as a stable yet nimble partner for global distributors and CROs, offering scalable collaboration, co-marketing, and channel-friendly programs to accelerate adoption of new QA products.